EXOPRO: How Does Prostate Cancer Metastasize? Studying the Role of Secreted Packages (Exosomes) From Fat Tissue in Lean and Obese Patients
Study Details
Study Description
Brief Summary
The investigators will be collecting prostate and fat tissue from participants undergoing radical prostatectomy to culture and study in the laboratory.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Both obesity and prostate cancer are major health problems in the UK, affecting 1 in 3 and 1 in 8 men respectively. Moreover, obesity increases the risk of developing aggressive disease and the risk of prostate cancer spreading. How this happens is not known. The investigators want to understand how fat cells communicate with prostate cancer cells. Investigators will be collecting prostate and fat tissue from radical prostatectomy participants for culture, in particular to look at exosome communication.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Obese patients BMI > 25 |
Procedure: Robotic Radical Prostatectomy
Routine NHS Radical Prostatectomy
|
| Lean patients BMI < or = 25 |
Procedure: Robotic Radical Prostatectomy
Routine NHS Radical Prostatectomy
|
Outcome Measures
Primary Outcome Measures
- Determine functional differences of peri-prostatic adipose tissue from lean vs obese patients on prostate cancer cell lines [Through to study completion, on average 3 years]
Proliferation, migration, invasion, apoptosis and epthelial-mesenchymal transition assays will be performed using isolated exosomes on prostate cancer cell lines
- Identification of exosomal small RNAs transferred between human adipose tissue to prostate cancer cells lines [Through to study completion, on average 3 years]
Exosomal RNA transferred from human adipose tissue to prostate cancer cell lines will be isolated using a tagged magnetic bead isolation method and sequenced to identify transferred small RNAs
- Assess how exosomal small RNAs from lean vs obese patients affect cancer regulation [Through to study completion, on average 3 years]
Prostate cancer cell lines will be treated with isolated exosomes, then parental and treated cells sequenced to identify differentially expressed RNA and underlying changes
- Attempt to replicate functional changes observed [Through to study completion, on average 3 years]
Treatment of prostate cancer cell lines with microRNA mimics or inhibitors and comparison of changes with exosome treated cell lines
Eligibility Criteria
Criteria
Inclusion Criteria:
- All men undergoing radical prostatectomy at Charing Cross Hospital
Exclusion Criteria:
- Patients unable to consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Charing Cross Hospital, Imperial College Healthcare NHS Trust | London | United Kingdom | W68RF |
Sponsors and Collaborators
- Imperial College London
- Imperial College Healthcare NHS Trust
- Experimental Cancer Medicine Centres
Investigators
- Principal Investigator: Charlotte Bevan, PhD, Imperial College London
- Principal Investigator: Mathias Winkler, FRCS, Imperial College Healthcare NHS Trust
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19HH5065